Case Study · Supply Interruption · 2022
February 2022. Four companies make 90% of America's baby formula. The largest domestic plant — producing 20% of the supply — is shut down by the FDA after bacterial contamination kills two infants. Within months: 74% of store shelves empty. Ten states are 90% out of formula. Parents queue at food banks. Infants who need specialized formula — the children with severe allergies or metabolic disorders for whom this plant was the only source — have nothing to fall back on. The most vulnerable population. No backup supply. No plan.
United States · February – Summer 2022
The 2022 baby formula shortage had visible warning signs years before it became a national crisis. The Art of Procurement analysis documents the pre-crisis timeline: a September 2019 FDA inspection of the Abbott Nutrition plant in Sturgis, Michigan found that Abbott "was not testing a representative sample of the product at the final stage before distribution to discover quality issues." Then COVID-19 hit and all FDA inspections stopped. Abbott went two years without a follow-up inspection — September 2019 to September 2021. When the FDA finally returned in September 2021, it "uncovered unsanitary conditions." In October 2021, an Abbott whistleblower submitted a 34-page complaint outlining concerns at the Sturgis facility. The FDA did not begin its formal inspection of the plant until January 31, 2022. In February 2022, Abbott voluntarily recalled Similac, Alimentum, and EleCare powdered formulas and shut down the Sturgis plant.
The Congressional testimony about the shortage documents the structural problem directly: "This plant produces 20 percent of the Nation's supply of baby formula." And Abbott was not unique in its scale — the PBS NewsHour account documents that "Abbott is one of just four companies that produce 90 percent of U.S. formula, and its February recall of several leading brands, including Similac, squeezed supplies that had already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns." The US normally produces 98% of the formula it consumes, with high tariffs that make foreign formula imports expensive and logistically complex. The supply concentration, the absence of imports, and the lack of any strategic reserve for infant nutrition combined to create a national crisis from a single plant closure. The CBS News account documents the peak: "Almost 74% of store shelves are empty, and 10 states are 90% out of baby formula." Parents sought formula from food banks, from friends, from doctors' offices, from informal networks. For infants with severe allergies or metabolic disorders — whose specialized formulas were produced primarily or exclusively at the Sturgis plant — the shortage was not just a hardship. It was a life-threatening supply failure.
Feb 2022
Plant Closure
20%
US Supply (1 plant)
74%
Shelves Empty (peak)
4 companies
Make 90% of US Supply
2 infant deaths
Triggering Event
Abbott's plant reopened on June 4, 2022 — only to be forced to close again on June 15 due to flooding from heavy rains that caused water damage to the facility. The National Academies report on the shortage documents this secondary closure as a further complication in an already-strained situation. The Center for American Progress analysis highlights the specific catastrophe for the most vulnerable group: "The Abbott plant in Michigan held a near monopoly on the production of specialized formulas that thousands of people rely on." These specialized formulas — for infants with phenylketonuria (PKU), severe milk protein allergies, maple syrup urine disease, and other metabolic and digestive conditions — are not optional nutrition for the children who need them. They are the only safe food source. For these families, the 2022 shortage was not a matter of searching for a different brand. It was a medical emergency produced by a supply chain with no redundancy for products with no substitutes.
The Science of Supply
Think of infant formula concentration risk differently from supply concentration in consumer goods. If the sole US manufacturer of a specific brand of breakfast cereal closes, consumers can switch to another brand. If the sole source of a specialized infant formula for a child with phenylketonuria closes, that child cannot eat anything else available on grocery shelves — and diluting the formula, switching to another brand, or trying homemade alternatives is dangerous or medically impossible. The Center for American Progress account describes the specific horror of the specialized formula shortage: families had "few or no other viable alternatives" for children who require formulas precisely calibrated for specific metabolic conditions. For standard formula, the shortage was a hardship. For specialized formula, it was a medical crisis with no equivalent to simply buying a different brand.
The FTC market analysis of the 2022 shortage documents the structural factors: four companies produce 90% of US formula; high tariffs on foreign formula (making imports uncompetitive in normal markets); and a WIC program that contracts with a single manufacturer per state for its subsidized formula — concentrating market share further and reducing competition. The Art of Procurement timeline of the crisis shows the regulatory failure: the FDA had documented quality concerns at Sturgis in 2019, a whistleblower had filed a detailed complaint in October 2021, and the formal inspection didn't begin until January 2022. The gap between "quality issue identified" (2019) and "plant closed" (2022) was a three-year regulatory lag during which the vulnerability was known but not addressed. The CNBC account of the closure notes that Gerber increased its formula supply by 50% in March and April — which was too late to prevent the peak shortage, but confirms that the market had production capacity that simply hadn't been needed when Abbott was supplying 20% of the market.
The CNBC account of the crisis notes that the FDA said it would "increase baby formula imports to the U.S., which normally produces 98% of the formula that consumers use." The 98% domestic production figure reflects both supply chain efficiency (formula is heavy and expensive to ship) and regulatory barriers (foreign formula must meet FDA standards, and most foreign manufacturers hadn't gone through the US registration process). The "Operation Fly Formula" program that the US government launched — using military aircraft to fly formula from European manufacturers — was necessary precisely because there were no pre-existing authorized import channels at scale. A product that infants literally cannot survive without had no emergency import pipeline, because nobody had built one when it wasn't needed.
Timeline
01
September 2019: FDA inspection of Sturgis plant documents Abbott not testing representative samples at final stage before distribution. COVID pandemic halts inspections. Abbott goes 2 years without follow-up (2019–2021). September 2021: FDA returns — finds unsanitary conditions. October 2021: Whistleblower submits 34-page complaint to FDA. FDA does not begin formal inspection until January 31, 2022. Supply chain already strained from COVID disruptions. Out-of-stock rate hits 11% by January 2022.
02
February 17, 2022: Abbott voluntarily recalls Similac, Alimentum, EleCare powdered formulas produced at Sturgis. Shuts down the plant. Trigger: four infants ill from Cronobacter sakazakii bacterial infections; two die. FDA inspection confirms: bacterial contamination in production areas, leaky roof, lax safety protocols. Sturgis had produced 20% of US formula supply and was near-monopoly for specialized metabolic formulas. No emergency reserve. No import pipeline. Crisis develops rapidly.
03
Spring 2022: Shortage peaks. 74% of store shelves empty nationally. 10 states 90% out of formula. Parents seek formula from food banks, friends, doctors' offices, online networks. Families of infants with metabolic disorders: no alternatives for some specialized formulas. Government launches "Operation Fly Formula" — US military aircraft fly formula from European manufacturers. Gerber increases supply 50%; Reckitt +30%. Abbott reaches consent decree with FDA to reopen June 4, 2022. Plant closes again June 15 due to flooding.
04
2022–present: US government and FDA begin review of formula market concentration. FTC publishes analysis of infant formula supply chain. Congressional hearings document the inspection failures. Regulatory changes: FDA improves inspection frequency. Some import pathways opened. Market diversification discussions ongoing. The shortage exposed that the US had no emergency supply of infant nutrition — the one category of food for which some consumers have no viable alternatives. DOJ begins investigation of Abbott plant conduct.
Human Decisions
The structural failures
The Congressional testimony is explicit: "This plant produces 20 percent of the Nation's supply of baby formula." Four companies produce 90% of the US supply. The US produces 98% of what it consumes, with high tariff barriers to imports. When one of the four companies' largest plant shut down, the market had no ability to immediately fill the gap — the other three were already running at or near capacity, and foreign manufacturers weren't approved for US sale. This is the market structure that made a single plant closure into a national emergency. It is exactly the type of concentration that the 1973 oil embargo should have made familiar: when critical supply is concentrated in a small number of sources, the failure of one creates a crisis that the remaining capacity cannot absorb.
The Art of Procurement timeline documents the regulatory failure precisely: quality issue documented in 2019; two-year inspection gap due to COVID; unsanitary conditions found September 2021; whistleblower complaint October 2021; formal inspection not beginning until January 2022; plant closure February 2022. In the three years between the initial quality finding and the closure, no action was taken that would have prevented the bacteria-related infant illnesses or enabled an earlier, more managed response to the closure. The absence of emergency formula reserves — not just strategic reserves for adults but for infants — meant there was no buffer to absorb the transition when the closure finally came.
The most vulnerable population
The 2022 shortage revealed the specific cruelty of supply interruptions targeting the most vulnerable: infants cannot advocate for themselves, cannot switch to an alternative voluntarily, and in some cases — particularly those with metabolic disorders — literally cannot survive on available substitutes. The CAP analysis is direct: families of infants with severe allergies or metabolic disorders "faced serious, dangerous medical risks as a result of the shortage." For these families, the shortage was not an inconvenience. It was a medical crisis produced by the absence of any emergency supply system for a product with no viable substitute for those who most need it.
The CAP analysis of the shortage documents that low-income families relying on WIC were disproportionately affected. WIC contracts with a single manufacturer per state — which had created concentrated market share for Abbott and meant that WIC recipients had no access to other manufacturers' products without losing their WIC benefit. The families least able to absorb an emergency (least financial flexibility, least ability to stockpile, least internet access to find scarce formula through informal networks) were the most exposed to the shortage. Supply concentration and population vulnerability are correlated in the infant formula market: the market that concentrated supply was also the market that WIC recipients had the least ability to leave.
The cascade lesson
The 2022 baby formula shortage is the supply interruption case study for domestic concentration risk — the version of supply chain vulnerability that doesn't require an OPEC embargo, a Japanese earthquake, or a Suez Canal grounding. A single FDA closure of a single domestic plant created a national shortage of infant nutrition. The concentration was visible and measurable before it became catastrophic: four manufacturers, 90% of supply, high tariff barriers to imports, no strategic reserve, and regulatory inspections that had lapsed during COVID. The warning signs accumulated for years. The shortage arrived anyway. For household preparedness, the baby formula shortage teaches the most personal lesson in this series: if your household includes anyone who depends on a specific product with no viable substitute — an infant, a person on dialysis, a child with a metabolic condition, someone with a severe allergy — that product's supply chain is a household emergency planning priority. The Strategic Petroleum Reserve exists because of 1973. The baby formula shortage of 2022 left a generation of families wondering why no equivalent existed for infant nutrition.
What You Can Do Now
The baby formula shortage is specifically a lesson about supply preparation for populations with no alternatives. These five actions translate that lesson into household preparedness for everyone with a non-negotiable supply dependency.
The 2022 shortage hit families who were buying formula week to week — as the JIT supply chain assumed they would. Maintaining a 2–4 week buffer of your specific formula brand, rotated so it stays within expiration, means that a local store shortage or a product recall gives you time to find alternatives without an emergency. For specialized formula, consider an 8-week buffer given the limited alternative options available if your specific product becomes unavailable.
Infant supply preparedness guideThe specialized formula crisis of 2022 was most severe for the families who had no plan because they'd never needed one — the formula had always been available. For any household member dependent on specialized formula, a feeding tube formula, a restricted-ingredient nutrition product, or any other medical nutrition with no viable substitute, having a written contingency plan — including alternative brands, your physician's guidance on substitution, and the contact for the manufacturer — means you're not researching under emergency conditions when supplies run short.
Medical nutrition supply guideEvery household should be able to answer this question: which supplies does our household need where there is no acceptable alternative? For families with infants on specialized formula, this is obvious. For families with members on specific medications, it may include medications with no generic substitute. For families with severe allergies, it includes specific safe food products. These "no alternative" items are the highest priority for buffer stock maintenance — because a shortage of a substitutable item is an inconvenience, while a shortage of a no-substitute item is a potential medical crisis.
Emergency supply planning guideThe baby formula market's four-company, 90%-concentration structure is unusual in its extremity but not unique in its principle. Pharmaceuticals, medical devices, and specialty food products for specific dietary needs often have similar concentration. Understanding which of your household's critical products come from one or two domestic manufacturers — and what happens if that manufacturer has a quality issue, a plant fire, or a recall — is the supply chain risk audit that the 2022 shortage showed most households hadn't done.
Supply chain resilience guideDuring the 2022 shortage, parents found formula through food banks, through doctor's offices, through informal community networks, and through online groups. These channels existed but were invisible to families who had never needed them. Knowing your community's emergency supply resources — food banks, WIC offices, community groups, your pediatrician's network — before a shortage occurs means you can access them in the first hours of a shortage rather than discovering them after the visible sources are exhausted.
Community resource network guideSupply interruption case study series
The 1973 oil embargo covers geopolitical supply cutoff. Tōhoku 2011 covers just-in-time failure. The Suez Canal 2021 covers chokepoint vulnerability. Together, they document every major supply interruption failure mode in the modern record.
Full supply interruption case study seriesSources